Ann: HeartWare Announces Date for FDA Advisory Co, page-7

re: Ann: HeartWare Announces Date for FDA Adv... http://www.zacks.com/stock/news/71795/Thoratec+Downgraded+to+Neutral+-+Analyst+Blog However, there is no imminent competitive threat from HeartWare in the DT segment as its product is not expected to be launched till 2015. It appears that the hyper-growth phase enjoyed by Thoratec has stabilized to more normalized growth. Thoratec has demonstrated expertise in product development even as HeartWare is expected to close the technological gap.